ASH 2020 – Multiple Myeloma

The analysis of updated efficacy and safety data from the ANCHOR study of melphalan flufenamide (melflufen) + dexamethasone and daratumumab or bortezomib in patients with RRMM demonstrated encouraging treatment efficacy that was well tolerated. Read More ›

This updated analysis of a phase 1, first-in-human study of REGN5458 in heavily pretreated patients with RRMM is consistent with previous findings, showing an acceptable safety profile and deep and durable responses. Read More ›

This phase 1/2 study demonstrated favorable efficacy and low rates of toxicity with low doses of P-BCMA-101 CAR T-cells in patients with RRMM. The favorable safety profile prompted a protocol amendment to allow fully outpatient administration. Read More ›

Results from a phase 1 study of talquetamab, a first-in-class bispecific antibody, show encouraging clinical activity with manageable toxicity in heavily pretreated patients with RRMM. The study is ongoing to identify a dose for phase 2 investigation. Read More ›

The updated analysis of the phase 1 study of teclistamab in patients with RRMM shows favorable efficacy and manageable safety, and supports the planned phase 2 monotherapy trial at 1500 μg/kg administered subcutaneously. Read More ›

The IKEMA study interim analysis showed isatuximab + carfilzomib and dexamethasone resulted in a clinically meaningful improvement in depth of response, with more patients reaching minimal residual disease–negativity compared with carfilzomib and dexamethasone alone. Read More ›

Updated efficacy and safety results of the phase 2 GRIFFIN study (NCT02874742) in patients with transplant-eligible, newly diagnosed multiple myeloma who received daratumumab plus lenalidomide, bortezomib, and dexamethasone. Read More ›

Results from a phase 3 study of circularly permuted tumor necrosis factor–related apoptosis-inducing ligand (TRAIL) + thalidomide and dexamethasone demonstrated this was a safe and effective treatment for patients with RRMM, including those with a poor prognosis. Read More ›

Talquetamab, a first-in-class bispecific antibody, showed encouraging efficacy with manageable toxicity in heavily pretreated patients with RRMM. An ongoing phase 2 investigation will determine the optimal dosing. Read More ›